Clinical Trial Update: Taxotere Prostate Cancer New Indication Registration Trial in China [Phase 3]

View source ↗

Summary

Phase 3 registration trial of Taxotere (docetaxel) for prostate cancer in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED